Trial
NCT04543279
Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Washington University School of Medicine
Collaborators
Rigel Pharmaceuticals
Condition
Myelofibrosis
Intervention
Fostamatinib
Why stopped
Low accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-12-15